近日,东曜药业发布公告称,截至2025年9月30日止九个月,公司营业收入为6.22亿元,较去年同期下降23%,主要原因是自研产品的市场竞争愈加激烈。净利润方面,公司在此期间出现亏损,净亏损为337万元,而去年同期则实现净利润3540万元。在资产负债表方面,截至2025年9月30日,公司流动资产为6.56亿元,非流动资产为7.21亿元,流动负债为2.66亿元,非流动负债为3.85亿元,净资产总额为...
Source Link近日,东曜药业发布公告称,截至2025年9月30日止九个月,公司营业收入为6.22亿元,较去年同期下降23%,主要原因是自研产品的市场竞争愈加激烈。净利润方面,公司在此期间出现亏损,净亏损为337万元,而去年同期则实现净利润3540万元。在资产负债表方面,截至2025年9月30日,公司流动资产为6.56亿元,非流动资产为7.21亿元,流动负债为2.66亿元,非流动负债为3.85亿元,净资产总额为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.